AroCell: resuming coverage following completion of rights issue

Research Note

2019-12-10

16:23

We resume coverage following completion of the rights issue where Redeye acted as financial advisor. Factoring in the transaction and the new number of outstanding shares, we also present a new fair value range.

OB

Oscar Bergman

Sign up for free to continue

Already a member?

Sign in

Disclosures and disclaimers

Premium Plan required to unlock

Unlock companies to access

more high quality research.